John B Moriarty
CIK 1564621 · Chief Legal Officer · last filed 2026-06-22
John B Moriarty is a Chief Legal Officer who has filed 58 SEC Form 4 insider transactions across 6 companies since 2018. The most recent filing, for KARD, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$252.8K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.3M across reported positions. 27 SEC filings were submitted jointly with ALEXION PHARMACEUTICALS, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Chief Legal Officer | 47,784 | $14.79 | $706.7K | $0 | 1 | 2026-06-22 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Chief Legal Officer | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | Chief Legal Officer | 74,557 | $7.84 | $584.5K | -$252.8K | 5 | 2026-01-09 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Legal Officer | 0 | $58.70 | $0 | $0 | 2 | 2024-01-23 |
| OLMA | EVP, Ch. Legal Officer & Sec. | — | $8.22 | — | $0 | 3 | 2023-02-02 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | EVP, General Counsel | 0 | — | — | $0 | 7 | 2020-07-02 |
Recent Filings
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | KARD | Grant (A) | +47,784 | $0 | EDGAR |
| 2026-02-27 | Avidity Biosciences, Inc. (RNAM) Delisted | Disp (D) | −92,054 | $0 | EDGAR |
| 2026-01-09 | RNA | Sell (S) | −2,374 | -$171.5K | EDGAR |
| 2025-12-19 | RNA | Mixed | +29,176 | -$1.93M | EDGAR |
| 2025-08-05 | RNA | Sell (S) | −2,245 | -$81.3K | EDGAR |
| 2025-01-08 | RNA | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-08-05 | RNA | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-01-23 | Mirati Therapeutics, Inc. (MRTX) Delisted | Disp (D) | −72,335 | $0 | EDGAR |
| 2023-08-10 | Mirati Therapeutics, Inc. (MRTX) Delisted | Grant (A) | +22,297 | $825.0K | EDGAR |
| 2023-07-20 | OLMA | Notice (144) | −5,265 | -$48.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.